TABLE 1.
Patient and tumor characteristics
| N (%) | Median | Range | |
|---|---|---|---|
| Age (in years) | 6.2 | 0.6–23.4 | |
| <6 | 29 (46.8%) | ||
| ≥6 | 33 (53.2%) | ||
| Gender | |||
| Male | 38 (61.3%) | ||
| Female | 24 (38.7%) | ||
| Tumor size (cm) | 62 | 2.9 | 0.2–5.2 |
| ≤5 cm | 60 (96.8%) | ||
| >5 cm | 1 (1.6%) | ||
| Missing | 1 (1.6%) | ||
| RT dose (Gy) | 45 | 36a–47.4 | |
| No RTb | 5 (8.1%) | ||
| 45 | 51 (82.2%) | ||
| <45 | 1 (1.6%) | ||
| >45 | 2 (3.2%) | ||
| Missing | 3 (4.8%) | ||
| Follow-up (in years) | 62 | 7.8 | 0.5–10.7 |
| Disease status at week 12 | |||
| CR | 15 (24.2%) | ||
| PR | 31 (50.0%) | ||
| SD | 7 (11.3%) | ||
| PD | 2 (3.2%) | ||
| Unknown | 7 (11.3%) | ||
a
One patient was enrolled as Group III but was subsequently determined to have microscopic residual disease, so a dose of 36 Gy was assessed as appropriate. The patient’s response was classified as CR.
b
Two had early progression (at Day 78 and 81); the other three did not progress but went off protocol therapy before week 13 for reasons of “physician determination,” “refusal by patient/parent,” and “Intolerable toxicity.”